Deals channel feed

Roche isn’t done lin­ing up new col­lab­o­ra­tions in the hot field of drug­ging RNA. Here’s one more

5 years ago

Edg­ing to­ward a piv­otal read­out, Bio­gen picks a new dis­cov­ery part­ner for oph­thalmic gene ther­a­py

5 years ago

Mil­len­do braces for deep cuts af­ter its last clin­i­cal ef­fort ends in de­feat and a last search for a way to end things

5 years ago

Ab­b­Vie bails on So­sei Hep­tares pact for nov­el neu­rol­o­gy can­di­dates in blow to dis­cov­ery out­fit's A-list Rolodex

5 years ago

Charles Riv­er bags an­ti­body dis­cov­ery-fo­cused Dis­tri­b­u­tion Bio for $104M, sig­nal­ing re­turn to pre-pan­dem­ic buy­out spree

5 years ago

In quick start to new year's M&A, Arvelle Ther­a­peu­tics hands reins to An­geli­ni as it nears EU ap­proval for cenoba­mate

5 years ago
R&D

A $6B CVR goes pfffft as the game clock runs out on a New Year's dead­line for Bris­tol My­er­s' liso-cel ap­pli­ca­tion

5 years ago

Phar­ma heavy­weight Pfiz­er step­ping in­to the prostate can­cer ring with Ab­b­Vie af­ter ink­ing a $4.2B al­liance with My­ovant

5 years ago

Am­gen hands off rights to lep­rosy, tu­ber­cu­lo­sis med picked up as part of $13.4B Ote­zla deal

5 years ago
Manufacturing

Rid­ing on rosy es­ti­mates of Zol­gens­ma sales, Re­genxBio sells part of its roy­al­ty for $200M

5 years ago
Cell/Gene Tx

Nek­tar sells off roy­al­ties on its 2 ap­proved drugs for $150M in cash, re­dou­bling fo­cus on I-O can­di­dates

5 years ago

Warp Speed bets $356M to mass man­u­fac­ture a Mer­ck drug for se­vere Covid-19

5 years ago
Coronavirus

A neigh­bor­ly vis­it turns in­to a bid­ding war: How Dan Skovron­sky se­cured Eli Lil­ly's lat­est $1B buy

5 years ago

A busy, buzzy Ver­tex finds a high-pro­file part­ner in the RNA-drug­ging world to launch a fresh dis­cov­ery ef­fort

5 years ago

Look­ing to build a 'd­ual sourcing' sup­ply chain, WuXi Bi­o­log­ics shells out $183M for Bay­er drug sub­stance plant

5 years ago
Outsourcing

Patrick Soon-Sh­iong merges trou­bled 'moon shot' Nan­tK­west and cell ther­a­py play Im­mu­ni­ty­Bio in late-stage ex­pan­sion

5 years ago
Cell/Gene Tx

Agios piv­ots away from on­col­o­gy, auc­tion­ing off can­cer pipeline for $2B and shift­ing the spot­light in re­struc­tur­ing

5 years ago

Col­orec­tal drug can­di­dates fo­cal point of new col­lab­o­ra­tion be­tween Servi­er, Cel­sius Ther­a­peu­tics

5 years ago

Glax­o­SmithK­line joins So­sei's who's-who list of clients with glob­al li­cens­ing pact for IBD small mol­e­cules

5 years ago

Ul­tragenyx bets up to $304M on an old No­var­tis drug for an ul­tra-rare bone dis­ease

5 years ago

Mer­ck­'s Roger Perl­mut­ter con­tin­ues spin­ning deals, putting up $1B+ for Janux Ther­a­peu­tics and its T cell en­gagers

5 years ago

Af­ter los­ing race for first to mar­ket in lu­pus nephri­tis, Au­rinia taps Ot­su­ka for vo­closporin li­cens­ing pact abroad

5 years ago

Glax­o­SmithK­line plumbs the dis­cov­ery field (again), bet­ting up to $815M for the lat­est add-on to its on­col­o­gy pipeline

5 years ago

Build­ing its neu­ro pipeline, No­var­tis antes up $210M cash to buy a biotech part­ner drug­ging 'both fla­vors' of NM­DA

5 years ago
First page Previous page 82838485868788 Next page Last page
A service from the Financial Times